Avecho Biotechnology LimitedASX: AVE

Avecho meets TGA ahead of Phase III Clinical Trial

· Issued by Avecho Biotechnology Limited

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Avecho Biotechnology Limited has announced that it met with the Australian Therapeutic Goods Administration to discuss its Phase III clinical trial design for insomnia treatment. The TGA confirmed that no changes are needed to the trial design, allowing Avecho to proceed with patient recruitment as planned. Avecho aims to be the first company to gain regulatory approval for a Phase III cannabidiol trial in Australia with its oral CBD soft-gel capsule.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Avecho Biotechnology Limited on 6ix

Earlier from Avecho Biotechnology

Later from Avecho Biotechnology

All Avecho Biotechnology news releases